DiogenX’s website
Marseille, FR · 5 known investors
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes. It focuses on new treatment options for diabetic patients as an alternative to lifelong exogenous insulin.
BiotechDeep TechDigital HealthHealthtech
Founders & leadership
Investors · 5
Competitors · 10
by search overlapargenx6 shared keywordsargenx is an immunology company that operates an antibody innovation ecosystem where scientists and antibody engineers develop novel targets, disease pathways, and therapeutic antibodies. It builds a proprietary portfolio of first-in-class product candidates, engineered with academic partners, to translate immunology research into medicines for patients.
Gendx5 shared keywordsGenDx is a molecular diagnostics company specializing in HLA typing and other reagents and software for pre- and post-transplant testing in diagnostic laboratories. It serves the transplantation and personalized healthcare field, offering NGS-based HLA typing products, software, and educational support.
Regenx Biosciences5 shared keywordsREGENXBIO is a gene therapy company developing treatments for rare and retinal diseases using its NAV Technology Platform of viral vectors, which it also licenses to other pharmaceutical and biotech companies. It operates a late-stage clinical pipeline and manufactures its investigational gene therapies at its facility in Rockville, MD.
Orogentx4 shared keywordsOrogen Therapeutics is a drug discovery company that uses AI-enabled DNA-encoded library (DEL) technology and machine learning to identify novel small-molecule compounds targeting cytokine-related immuno-inflammatory disorders. The company focuses on developing oral small-molecule candidates for therapeutic areas including dermatology, rheumatology, and gastroenterology.
Phigenix3 shared keywordsPhigenix develops personalized medicine for cancer, including companion diagnostics and targeted therapies for prostate and breast cancer patients. Its work centers on early detection and targeted inhibition of PAX2 and EN2 oncogenes and a cancer vaccine using Human Beta Defensin-1 (DEFB1) mRNA to direct the immune system against cancer cells.
Origene3 shared keywordsOriGene supplies research reagents including primary antibodies for flow cytometry, transfection kits (EZ-LNP and ProteanFect), RNAi gene silencing tools, and control solutions for life science laboratories. Its products serve researchers in molecular and cell biology.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Genedx3 shared keywordsGeneDx provides genetic testing for rare and inherited conditions, including exome, genome, trio, and prenatal sequencing, paired with clinical interpretation and a large rare disease dataset. It serves clinicians, patients, and biopharma partners to support earlier diagnoses and precision medicine.
Endogenex3 shared keywordsEndogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes. Developed in partnership with Mayo Clinic, the therapy aims to help patients manage blood glucose levels and slow disease progression.
Genomadix3 shared keywordsGenomadix develops the Genomadix Cube, a portable real-time qPCR molecular diagnostic platform that performs point-of-need pharmacogenetic testing, including CYP2C19 genotyping from a cheek swab with results in about an hour. It serves clinicians treating acute conditions such as stroke, TIA, and acute coronary syndrome to guide antiplatelet therapy decisions.
Companies competing with DiogenX’s website for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does DiogenX’s website do?
- DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes. It focuses on new treatment options for diabetic patients as an alternative to lifelong exogenous insulin.
- Who founded DiogenX’s website?
- DiogenX’s website was founded by Benjamin Charles, Patrick Collombat, Jean-Pascal Tranié.
- Who are DiogenX’s website's investors?
- DiogenX’s website's investors include AdBio partners, Roche Venture Fund, Boehringer Ingelheim Venture Fund, Sunstone Capital, JDRF T1D Fund.
- Where is DiogenX’s website headquartered?
- DiogenX’s website is headquartered in Marseille, FR.